Katarina Steding-Ehrenborg, Anders Nelsson, Henrik Engblom, Ellen Ostenfeld, Per M Arvidsson, Martin Magnusson, J Gustav Smith, Håkan Arheden
{"title":"低峰值摄氧量与心脏总容积的关系是亚临床舒张功能障碍的早期标志。","authors":"Katarina Steding-Ehrenborg, Anders Nelsson, Henrik Engblom, Ellen Ostenfeld, Per M Arvidsson, Martin Magnusson, J Gustav Smith, Håkan Arheden","doi":"10.1093/ehjimp/qyaf115","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Peak oxygen uptake (VO<sub>2</sub>peak) is closely related to total heart volume (THV) in healthy individuals. This study aimed to investigate (i) the association between VO<sub>2</sub>peak and THV in subjects with sub-clinical diastolic dysfunction, athletes, healthy controls, and patients with established heart failure with and without preserved ejection fraction (HFpEF and HFrEF), and (ii) whether VO<sub>2</sub>peak/THV-index can distinguish between subjects with sub-clinical diastolic dysfunction, HFpEF, HFrEF, and healthy controls.</p><p><strong>Methods and results: </strong>Seventy participants were included: 15 with sub-clinical diastolic dysfunction (defined as showing only 1-2 echocardiographic signs of diastolic dysfunction, not meeting clinical diagnostic criteria), 10 athletes, 15 healthy controls, and 30 heart failure patients (15 HFpEF and 15 HFrEF). VO<sub>2</sub>peak was assessed by cardiopulmonary exercise testing and THV by cardiovascular magnetic resonance imaging. In sub-clinical diastolic dysfunction, THV was a weak determinant of VO<sub>2</sub>peak (<i>R</i> <sup>2</sup> = 0.41, <i>P</i> = 0.01), and even weaker in heart failure (<i>R</i> <sup>2</sup> = 0.16, <i>P</i> = 0.03). However, THV strongly predicted VO<sub>2</sub>peak in athletes and controls combined (<i>R</i> <sup>2</sup> = 0.87, <i>P</i> < 0.0001). VO<sub>2</sub>peak/THV did not distinguish healthy controls from sub-clinical diastolic dysfunction but could reliably discriminate between healthy controls and patients with heart failure.</p><p><strong>Conclusion: </strong>Subjects with sub-clinical diastolic dysfunction may have an altered relationship between VO<sub>2</sub>peak and THV, approaching that of patients with established heart failure. Thus, this proof-of-concept study indicates that sub-clinical diastolic dysfunction constitutes a group of patients that may be of interest to follow over time to prevent continued deterioration of cardiac function. Furthermore, the VO<sub>2</sub>peak/THV ratio can be used to distinguish between healthy controls and overt heart failure.</p>","PeriodicalId":94317,"journal":{"name":"European heart journal. Imaging methods and practice","volume":"3 2","pages":"qyaf115"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12459250/pdf/","citationCount":"0","resultStr":"{\"title\":\"Low peak oxygen uptake in relation to total heart volume as an early marker of sub-clinical diastolic dysfunction.\",\"authors\":\"Katarina Steding-Ehrenborg, Anders Nelsson, Henrik Engblom, Ellen Ostenfeld, Per M Arvidsson, Martin Magnusson, J Gustav Smith, Håkan Arheden\",\"doi\":\"10.1093/ehjimp/qyaf115\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>Peak oxygen uptake (VO<sub>2</sub>peak) is closely related to total heart volume (THV) in healthy individuals. This study aimed to investigate (i) the association between VO<sub>2</sub>peak and THV in subjects with sub-clinical diastolic dysfunction, athletes, healthy controls, and patients with established heart failure with and without preserved ejection fraction (HFpEF and HFrEF), and (ii) whether VO<sub>2</sub>peak/THV-index can distinguish between subjects with sub-clinical diastolic dysfunction, HFpEF, HFrEF, and healthy controls.</p><p><strong>Methods and results: </strong>Seventy participants were included: 15 with sub-clinical diastolic dysfunction (defined as showing only 1-2 echocardiographic signs of diastolic dysfunction, not meeting clinical diagnostic criteria), 10 athletes, 15 healthy controls, and 30 heart failure patients (15 HFpEF and 15 HFrEF). VO<sub>2</sub>peak was assessed by cardiopulmonary exercise testing and THV by cardiovascular magnetic resonance imaging. In sub-clinical diastolic dysfunction, THV was a weak determinant of VO<sub>2</sub>peak (<i>R</i> <sup>2</sup> = 0.41, <i>P</i> = 0.01), and even weaker in heart failure (<i>R</i> <sup>2</sup> = 0.16, <i>P</i> = 0.03). However, THV strongly predicted VO<sub>2</sub>peak in athletes and controls combined (<i>R</i> <sup>2</sup> = 0.87, <i>P</i> < 0.0001). VO<sub>2</sub>peak/THV did not distinguish healthy controls from sub-clinical diastolic dysfunction but could reliably discriminate between healthy controls and patients with heart failure.</p><p><strong>Conclusion: </strong>Subjects with sub-clinical diastolic dysfunction may have an altered relationship between VO<sub>2</sub>peak and THV, approaching that of patients with established heart failure. Thus, this proof-of-concept study indicates that sub-clinical diastolic dysfunction constitutes a group of patients that may be of interest to follow over time to prevent continued deterioration of cardiac function. Furthermore, the VO<sub>2</sub>peak/THV ratio can be used to distinguish between healthy controls and overt heart failure.</p>\",\"PeriodicalId\":94317,\"journal\":{\"name\":\"European heart journal. Imaging methods and practice\",\"volume\":\"3 2\",\"pages\":\"qyaf115\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12459250/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European heart journal. Imaging methods and practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/ehjimp/qyaf115\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European heart journal. Imaging methods and practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/ehjimp/qyaf115","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:健康个体的最大摄氧量(VO2peak)与心脏总容积(THV)密切相关。本研究旨在探讨(i)亚临床舒张功能不全受试者、运动员、健康对照、有和没有保留射血分数(HFpEF和HFrEF)的心力衰竭患者的VO2peak和THV之间的关系,以及(ii) VO2peak/THV指数是否可以区分亚临床舒张功能不全受试者、HFpEF、HFrEF和健康对照。方法和结果:70名参与者包括:15名亚临床舒张功能不全(定义为仅显示1-2个舒张功能不全的超声心动图征像,不符合临床诊断标准),10名运动员,15名健康对照,30名心力衰竭患者(HFpEF和HFrEF各15名)。心肺运动试验测定vo2峰值,心血管磁共振成像测定THV。在亚临床舒张功能不全时,THV是vo2峰值的弱决定因素(r2 = 0.41, P = 0.01),在心力衰竭时更弱(r2 = 0.16, P = 0.03)。然而,THV能很好地预测运动员和对照组的vo2峰值(r2 = 0.87, P < 0.0001)。VO2peak/THV不能区分健康对照和亚临床舒张功能障碍,但可以可靠地区分健康对照和心力衰竭患者。结论:亚临床舒张功能不全患者的vo2峰值与THV之间的关系可能发生改变,接近心力衰竭患者。因此,这项概念验证研究表明,亚临床舒张功能障碍患者可能有兴趣长期随访,以防止心功能持续恶化。此外,vo2峰值/THV比值可用于区分健康对照和明显的心力衰竭。
Low peak oxygen uptake in relation to total heart volume as an early marker of sub-clinical diastolic dysfunction.
Aims: Peak oxygen uptake (VO2peak) is closely related to total heart volume (THV) in healthy individuals. This study aimed to investigate (i) the association between VO2peak and THV in subjects with sub-clinical diastolic dysfunction, athletes, healthy controls, and patients with established heart failure with and without preserved ejection fraction (HFpEF and HFrEF), and (ii) whether VO2peak/THV-index can distinguish between subjects with sub-clinical diastolic dysfunction, HFpEF, HFrEF, and healthy controls.
Methods and results: Seventy participants were included: 15 with sub-clinical diastolic dysfunction (defined as showing only 1-2 echocardiographic signs of diastolic dysfunction, not meeting clinical diagnostic criteria), 10 athletes, 15 healthy controls, and 30 heart failure patients (15 HFpEF and 15 HFrEF). VO2peak was assessed by cardiopulmonary exercise testing and THV by cardiovascular magnetic resonance imaging. In sub-clinical diastolic dysfunction, THV was a weak determinant of VO2peak (R2 = 0.41, P = 0.01), and even weaker in heart failure (R2 = 0.16, P = 0.03). However, THV strongly predicted VO2peak in athletes and controls combined (R2 = 0.87, P < 0.0001). VO2peak/THV did not distinguish healthy controls from sub-clinical diastolic dysfunction but could reliably discriminate between healthy controls and patients with heart failure.
Conclusion: Subjects with sub-clinical diastolic dysfunction may have an altered relationship between VO2peak and THV, approaching that of patients with established heart failure. Thus, this proof-of-concept study indicates that sub-clinical diastolic dysfunction constitutes a group of patients that may be of interest to follow over time to prevent continued deterioration of cardiac function. Furthermore, the VO2peak/THV ratio can be used to distinguish between healthy controls and overt heart failure.